Medical-AI trial: finding early glaucoma from fundus photos with AI (GlaukomAI) — preventing blindness and cutting waits (NCT07668193)
A study evaluating whether the AI software GlaukomAI can detect glaucoma, a leading cause of irreversible blindness, at an early stage from fundus (back-of-eye) photographs. Current diagnosis needs multiple specialist visits and tests, causing long waits and delays. At an eye institute in Rome, Italy, Phase 1 uses 100 glaucoma and 100 healthy controls to assess accuracy (sensitivity and specificity). 1,200 patients; two phases.
Trial overview (primary data)
- StatusNot yet recruiting
- ConditionsGlaucoma
- InterventionsDEVICE: GlaukomAI (Sens-vue GlaukomAI)
- SponsorFondazione G.B. Bietti, IRCCS
- Target enrollment1,200 participants
- Period2026-10-01 〜 2028-05-01
Key points
- A study of whether the AI software GlaukomAI can detect glaucoma, a leading cause of irreversible blindness, early from fundus photographs.
- Current diagnosis needs multiple specialist visits and tests, causing long waits and delays.
- At an eye institute in Rome, Italy, in two phases; Phase 1 uses 100 glaucoma and 100 healthy controls in a case-control design.
- The primary outcome is diagnostic accuracy: sensitivity and specificity. Total 1,200, including referral-accuracy assessment.
- Fundus photos are simple; AI reading could triage crowded specialty clinics. An accuracy/referral evaluation, not an establishment of diagnosis replacement.
- Stage one is a case-control design of 100 glaucoma and 100 control eyes, extending to 1,200 with referral appropriateness assessed.
1Glaucoma takes sight that does not return
Glaucoma damages the optic nerve at the back of the eye little by little, narrowing the visual field, and because lost vision does not return (it is irreversible), it is one of the leading causes of blindness worldwide. Early on there are few symptoms, so it is often advanced by the time it is noticed.
That is why early detection matters, yet a confirmed diagnosis requires several tests (eye pressure, visual field, fundus, OCT) and repeated specialist visits, creating waits and delays.
2GlaukomAI, reading fundus photographs
The GlaukomAI this study evaluates tries to widen that entry point, aiming to detect early glaucoma by analyzing fundus (back-of-eye) photographs with AI. Per the registry summary, the study is conducted at an eye institute (IRCCS Fondazione G. B. Bietti) in Rome, Italy, in two phases.
Phase 1 enrolls 200 participants (100 with diagnosed glaucoma and 100 healthy controls) to assess, in a case-control design, how accurately GlaukomAI can tell them apart. The primary outcome is diagnostic accuracy: sensitivity (not missing disease) and specificity (not misclassifying). The overall size is 1,200, including an assessment of referral accuracy.
3Confirmed in two stages
The trial is built in two stages: first confirming that it can tell the difference, then examining whether the referrals it prompts were appropriate.
- 1Stage oneEnrol 200 — 100 diagnosed with glaucoma and 100 healthy controls
- 2Measure accuracyEvaluate sensitivity and specificity in a case-control design
- 3On to stage twoExtend to 1,200 in total and evaluate the appropriateness of referral
Glaucoma is a leading cause of blindness worldwide because lost vision does not return; early stages carry few symptoms, and confirming a diagnosis requires repeated visits for pressure, field, fundus and OCT testing. A fundus photograph can be taken as easily as at a health check or an optician, so AI reading could sort referrals sensibly into crowded specialist clinics.
Why it matters
A fundus photo can be taken at a health check or optical shop. If AI reading can flag suspected glaucoma before specialist referral, it could triage crowded specialty clinics. A case-control then referral-accuracy design is a sound way to evaluate a screening AI (this study is an evaluation stage, not an establishment of diagnosis replacement).
FAQ
Why does early glaucoma detection matter?
Does the AI replace the eye doctor diagnosis?
Sources (primary)
Source: ClinicalTrials.gov (U.S. NIH/NLM, public domain). This site does not provide medical advice. Verify the latest and exact details with the official source. This site is not endorsed or certified by the NIH/NLM.
- ClinicalTrials.gov (study record, original)
- NCT ID: NCT07668193